ABVC — ABVC Biopharma Share News
0.000.00%
Last trade - 00:00Brief: Abvc Biopharma Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: ABVC Biopharma Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements
Brief: ABVC Biopharma Inc On March 5, Leeds Chow Resigns As CFO Of Abvc Biopharma
Brief: ABVC Biopharma Secures $200,000 In First Cash Licensing Payment From Oncology Products Partner
Brief: ABVC Biopharma- Got Written Notification From Nasdaq, Indicating Co Regained Compliance With Listing Rules 5635(A)(1) And 5635(A)(2)
Brief: ABVC Biopharma Says Leeds Chow Informed Co He Is Suspending His Work As CFO
Brief: ABVC Biopharma & Biolite Entered Into Definitive Agreement With Oncox Biopharma To Collaborate On Combination Therapy
Brief: Abvc Collaboration With Oncox Biopharma, Abvc Expecting Aggregate Income Of $13.75 Million And Royalties Of Up To $12.50 Million
Brief: ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC
Brief: ABVC BioPharma Executes Global Licensing Term Sheet For Oncology, Hematology Products
Brief: ABVC Acquires $2.96 Million Worth Of Land In Asia With Stocks Priced At $3.50 Per Share
Brief: ABVC Biopharma Files For Offering 10.4 Million Shares By The Selling Stockholders
U.S. STOCKS ON THE MOVE-Amgen, Unum, US energy sector
U.S. STOCKS ON THE MOVE-Pure Storage, Pfizer, Southern First Bancshares
U.S. STOCKS ON THE MOVE-Gold miners, Dyne Therapeutics, Coinbase Global
ABVC BioPharma up on receiving $460 mln worth shares under licensing deal
Brief: ABVC BioPharma and its Subsidiary Receive $460 Mln From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees
Brief: ABVC BioPharma Receives U.S. Patent for ADHD Treatment
ABVC BioPharma rises on licensing agreement for ADHD drug